CNBC: "The Google for Investing Fintech"
Invest in the future with the future of investing. Search, discover, and invest in minutes – with Magnifi. No trade commissions.

No hidden execution charges.

Start investing today.
Learn more.
pixel

IMPL Insider Trading (Impel NeuroPharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $8,904,800.00
Insider Selling (Last 12 Months): $0.00

Impel NeuroPharma Insider Trading History Chart

This chart shows the insider buying and selling history at Impel NeuroPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Impel NeuroPharma Share Price & Price History

Current Price: $13.03
Price Change: Price Decrease of -0.42 (-3.12%)
As of 09/24/2021 01:00 AM ET

This chart shows the closing price history over time for IMPL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
CNBC: "The Google for Investing Fintech"
Invest in the future with the future of investing. Search, discover, and invest in minutes – with Magnifi. No trade commissions.

No hidden execution charges.

Start investing today.
Learn more.
pixel

Impel NeuroPharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2021Adrian AdamsCEOBuy20,000$13.99$279,800.0017,203View SEC Filing Icon  
4/27/2021Vivo Capital Viii, LlcMajor ShareholderBuy575,000$15.00$8,625,000.0098,927View SEC Filing Icon  
See Full Table
Insider Buying at Impel NeuroPharma?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Impel NeuroPharma and related companies.

SEC Filings (Institutional Ownership Changes) for Impel NeuroPharma (NASDAQ:IMPL)

86.72% of Impel NeuroPharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMPL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Impel NeuroPharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/23/2021Morgan Stanley7,888$69K0.0%N/A0.040%Search for SEC Filing on Google Icon
8/17/2021Woodline Partners LP119,615$1.06M0.0%N/A0.537%Search for SEC Filing on Google Icon
8/17/2021Zimmer Partners LP25,000$0.22M0.0%N/A0.112%Search for SEC Filing on Google Icon
8/17/2021Kohlberg Kravis Roberts & Co. L.P.3,802,639$33.65M0.1%N/A17.071%Search for SEC Filing on Google Icon
8/16/20215AM Venture Management LLC2,884,791$25.53M6.4%N/A12.950%Search for SEC Filing on Google Icon
8/16/2021California State Teachers Retirement System7,464$66K0.0%N/A0.034%Search for SEC Filing on Google Icon
8/16/2021venBio Partners LLC2,759,791$24.42M2.9%N/A12.389%Search for SEC Filing on Google Icon
8/16/2021Morgan Stanley7,888$69K0.0%N/A0.035%Search for SEC Filing on Google Icon
8/16/2021Pinz Capital Management LP6,188$55K0.0%N/A0.028%Search for SEC Filing on Google Icon
8/16/2021Charles Schwab Investment Management Inc.11,413$0.10M0.0%N/A0.051%Search for SEC Filing on Google Icon
8/16/2021State Street Corp46,298$0.41M0.0%N/A0.208%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp58,493$0.52M0.0%N/A0.263%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC50,942$0.45M0.0%N/A0.229%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.183,753$1.63M0.0%N/A0.825%Search for SEC Filing on Google Icon
8/12/2021JPMorgan Chase & Co.6,653$59K0.0%N/A0.030%Search for SEC Filing on Google Icon
8/11/2021BlackRock Inc.251,063$2.22M0.0%N/A1.127%Search for SEC Filing on Google Icon
8/11/2021Deutsche Bank AG3,196$28K0.0%N/A0.014%Search for SEC Filing on Google Icon
8/10/2021Norwest Venture Partners Xiv LP3,077,198$27.23M31.4%N/A13.814%Search for SEC Filing on Google Icon
8/3/2021Victory Capital Management Inc.112,730$1M0.0%N/A0.506%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Impel NeuroPharma logo
Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Read More on Impel NeuroPharma

Today's Range

Now: $13.03
Low: $12.92
High: $13.70

50 Day Range

MA: $15.79
Low: $10.40
High: $26.13

52 Week Range

Now: $13.03
Low: $6.90
High: $34.75

Volume

489,197 shs

Average Volume

382,203 shs

Market Capitalization

$254.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Impel NeuroPharma?

Impel NeuroPharma's top insider shareholders include:
  1. Vivo Capital Viii, Llc (Major Shareholder)
  2. Adrian Adams (CEO)
  3. Global Strategic Fund I Venbio (EVP)

Who are the major institutional investors of Impel NeuroPharma?

Impel NeuroPharma's top institutional investors include:
  1. Kohlberg Kravis Roberts & Co. L.P. — 17.07%
  2. Norwest Venture Partners Xiv LP — 13.81%
  3. 5AM Venture Management LLC — 12.95%
  4. venBio Partners LLC — 12.39%
  5. BlackRock Inc. — 1.13%
  6. Vanguard Group Inc. — 0.82%

Which major investors are buying Impel NeuroPharma stock?

In the last quarter, IMPL stock was purchased by institutional investors including:
  1. Kohlberg Kravis Roberts & Co. L.P.
  2. Norwest Venture Partners Xiv LP
  3. 5AM Venture Management LLC
  4. venBio Partners LLC
  5. BlackRock Inc.
  6. Vanguard Group Inc.
  7. Woodline Partners LP
  8. Victory Capital Management Inc.
During the previous year, these company insiders have bought Impel NeuroPharma stock:
  1. Vivo Capital Viii, Llc (Major Shareholder)
  2. Adrian Adams (CEO)
CNBC: "The Google for Investing Fintech"
Invest in the future with the future of investing. Search, discover, and invest in minutes – with Magnifi. No trade commissions.

No hidden execution charges.

Start investing today.
Learn more.
pixel